Siemens’ PETNET Solutions to Manufacture Navidea’s NAV4694, an Investigational Beta-amyloid Imaging Agent

Aug 21, 2013

Navidea’s investigational beta-amyloid positron emission tomography (PET) imaging agent, 18F-labeled NAV4694, to be manufactured at PETNET Solutions locations in the United States with expansion planned for next year


Siemens’ PETNET Solutions – a wholly owned subsidiary of Siemens Healthcare – has signed an agreement with Navidea Biopharmaceuticals that grants Siemens’ PETNET Solutions the right to manufacture Navidea’s Fluorine-18 labeled NAV4694, which is currently being assessed in Phase II and Phase III clinical trials as a beta-amyloid PET imaging agent. Under the terms of its agreement with Navidea, Siemens’ PETNET Solutions will initially manufacture NAV4694 at select U.S. radiopharmacies, with the possibility of expanding into additional PETNET Solutions locations next year.


“This agreement with Navidea reaffirms the commitment of Siemens’ PETNET Solutions to driving innovation in PET imaging by supporting the availability of new PET imaging agents with our manufacturing expertise and increasing patient access to new PET examinations,” said Dr. Christoph Zindel, CEO of Siemens’ PETNET Solutions, "and by manufacturing investigational PET imaging agents for clinical trials.”


“Navidea is committed to providing the medical community with valuable precision diagnostics like NAV4694, which is currently being assessed in Phase II and III clinical trials evaluating subjects with signs or symptoms of cognitive impairment such as Mild Cognitive Impairment and Alzheimer’s disease to improve diagnostic accuracy, clinical decision-making and ultimately patient care,” said Dr. Mark Pykett, CEO of Navidea. “We are pleased the NAV4694 clinical program will be supported by PETNET Solutions extensive manufacturing and dispensing expertise.”


Beta-amyloid plaque is one of the necessary pathological features of Alzheimer’s disease—the sixth leading cause of death in the United States. PET amyloid scans can help visualize beta-amyloid plaque in the living brain.



Contact for journalists:
Jeff Bell
Siemens Healthcare Media Relations
Phone: +1 610-448-1477; E-mail:

Follow us on Twitter at:



Launched in November 2011, Agenda 2013 is the initiative of the Siemens Healthcare Sector to further strengthen its innovative power and competitiveness. Specific measures, which will be implemented by the end of 2013, have been defined in four fields of action: innovation, competitiveness, regional footprint, and people development.


The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2012 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of around 1.8 billion euros. For further information please visit: